Opportunities center on rapid point-of-care and multiplex PCR tests, AI-assisted interpretation, cloud surveillance and high-sensitivity assays, driven by respiratory illness and healthcare investment
Rhinovirus Diagnostics Market
Dublin, Sept. 03, 2026 (GLOBE NEWSWIRE) — The “Rhinovirus Diagnostics Market Global Report 2026” has been added to ResearchAndMarkets.com’s offering.
The global rhinovirus diagnostics market is experiencing strong growth as healthcare systems increase their focus on early respiratory infection detection, rapid testing and advanced molecular diagnostics. The market is projected to grow from $1.58 billion in 2025 to $1.71 billion in 2026, representing a compound annual growth rate (CAGR) of 7.9%.
Growth during the historical period has been supported by the increasing prevalence of common colds and respiratory infections, wider adoption of molecular diagnostic techniques, expansion of hospital laboratory testing infrastructure and growing awareness of the benefits of early infectious disease diagnosis. The limitations of traditional culture-based viral detection methods have also encouraged laboratories and healthcare providers to implement faster, more sensitive rhinovirus testing solutions.
The rhinovirus diagnostics market is forecast to reach $2.33 billion by 2030, expanding at a CAGR of 8.2%. Key market growth drivers include rising demand for rapid point-of-care diagnostics, increasing investment in infectious disease surveillance, the expansion of multiplex respiratory pathogen panels and the integration of artificial intelligence into diagnostic interpretation. Personalized and precision medicine approaches for respiratory infections are also expected to support continued market development.
Major rhinovirus diagnostics market trends include the adoption of AI-assisted respiratory pathogen detection, growth in multiplex polymerase chain reaction testing and the development of high-sensitivity molecular assays for earlier identification of infections. Point-of-care rhinovirus diagnostic devices are becoming increasingly important in outpatient clinics and emergency care settings, where faster results can improve clinical decision-making, optimize patient management and help reduce the transmission of respiratory illnesses. Cloud-based infectious disease surveillance platforms are also strengthening the collection and analysis of respiratory infection data.
The rising prevalence of respiratory disorders is expected to remain a significant driver of market growth. Increasing air pollution and prolonged exposure to harmful pollutants are contributing to declining respiratory health and a higher burden of lung and airway conditions. Rhinovirus diagnostics enable healthcare professionals to identify infections quickly, support timely treatment decisions and reduce the risk of complications. According to information published by the National Center for Biotechnology Information in December 2023, global chronic obstructive pulmonary disease cases are expected to increase by 112 million and reach 592 million by 2050, representing 9.5% of the eligible population.
Diagnostic manufacturers are responding to market demand by developing rapid syndromic molecular platforms capable of detecting multiple respiratory pathogens from a single sample. In April 2023, bioMérieux received U.S. Food and Drug Administration 510(k) clearance for the BIOFIRE SPOTFIRE Respiratory Panel Mini and announced plans to pursue Clinical Laboratory Improvement Amendments waiver status. The panel can detect multiple respiratory pathogens, including human rhinovirus/enterovirus, at the point of care. Its rapid testing capabilities are designed to streamline clinical workflows and support timely treatment decisions in outpatient and emergency care environments.
Rising healthcare expenditure is also contributing to the expansion of the rhinovirus diagnostics market by improving access to advanced testing technologies and strengthening diagnostic infrastructure. Greater investment in medical technology enables healthcare organizations to adopt new molecular testing platforms, expand respiratory pathogen screening and increase testing capacity. In April 2025, the UK Office for National Statistics reported that healthcare spending in the country reached approximately £317 billion in 2024, a nominal increase of 6.5% compared with 2023.
North America was the dominant region in the rhinovirus diagnostics market in 2025, supported by established laboratory infrastructure, advanced healthcare systems and strong adoption of molecular diagnostic technologies. Asia-Pacific is expected to be the fastest-expanding region during the forecast period. The market analysis covers Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. Countries covered include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy and Spain.
Markets Covered:
1) By Offering: Kits And Assays; Instruments And Platforms; Services And Software
2) By Technology: Molecular Diagnostics; Antigen Detection; Serology
3) By Sample Type: Nasal Swabs; Throat Swabs; Nasopharyngeal Aspirates; Other Sample Types
4) By End User: Hospitals; Diagnostic Laboratories; Clinics; Other End Users
Subsegments:
1) By Kits And Assays: Molecular Diagnostic Kits (Polymerase Chain Reaction Based Assays); Rapid Antigen Detection Kits; Multiplex Respiratory Pathogen Panels
2) By Instruments And Platforms: Automated Immunoassay Analyzers; Point Of Care Diagnostic Devices; Next Generation Sequencing Platforms
3) By Services And Software: Laboratory Information Management Systems; Diagnostic Data Interpretation Software; Cloud Based Reporting And Surveillance Platforms
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026-2030 |
| Estimated Market Value (USD) in 2026 | $1.71 Billion |
| Forecasted Market Value (USD) by 2030 | $2.33 Billion |
| Compound Annual Growth Rate | 8.2% |
| Regions Covered | Global |
Companies Featured
- F. Hoffmann-La Roche AG
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Becton Dickinson and Company
- Quest Diagnostics Incorporated
- Danaher Corporation (Cepheid)
- Hologic Inc.
- Bruker Corporation (ELITechGroup SAS)
- bioMérieux SA
- Qiagen N.V.
- QuidelOrtho Corporation
- DiaSorin S.p.A.
- Seegene Inc.
- ARUP Laboratories Inc.
- Sansure Biotech Inc.
- SRL Inc.
- R-Biopharm AG
- CerTest Biotec S.L.
- SpeeDx Pty Ltd
- GeneFirst Limited
- Atila BioSystems Inc.
For more information about this report visit https://www.researchandmarkets.com/r/uzbkus
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
- Rhinovirus Diagnostics Market
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
